Teva launches phase III with MedinCell
The Israeli laboratory Teva announced the start of the phase III study of the antipsychotic olanzapine formulated with Montpellier Biotech’s long-acting technology MedinCell. Conducted in the United States, this trial will evaluate the efficacy and safety of what may be the first long-acting subcutaneous injectable formulation of olanzapine for the treatment of patients with schizophrenia.
American green light for TheracosBio
The FDA just cleared Brenzavvy (bexagliflozin) from American biotech TheracosBio for the treatment of adults with type 2 diabetes, in addition to diet and exercise to improve glycemic control. In several phase III studies, this sodium glucose cotransporter type 2 (SGLT2) inhibitor significantly reduced fasting blood sugar following 24 weeks.
VOS INDICES
source
MSD stops a test with the Keytruda
MSD announced the halt for “futility” of the phase III trial evaluating its flagship drug, Keytruda (pembrolizumab), in combination with enzalutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-responsive prostate cancer (mHSPC). At the interim analysis, this combination did not demonstrate an improvement in overall survival in patients.
Selected for you
